|
IL63907A0
(en)
|
1980-09-24 |
1981-12-31 |
Cetus Corp |
Diagnostic method and antibody probe for use therein
|
|
US4582788A
(en)
|
1982-01-22 |
1986-04-15 |
Cetus Corporation |
HLA typing method and cDNA probes used therein
|
|
ATE53862T1
(de)
|
1982-01-22 |
1990-06-15 |
Cetus Corp |
Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
|
|
US4683194A
(en)
|
1984-05-29 |
1987-07-28 |
Cetus Corporation |
Method for detection of polymorphic restriction sites and nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
CA1284931C
(en)
|
1986-03-13 |
1991-06-18 |
Henry A. Erlich |
Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
|
|
CA1338457C
(en)
|
1986-08-22 |
1996-07-16 |
Henry A. Erlich |
Purified thermostable enzyme
|
|
US5093330A
(en)
|
1987-06-15 |
1992-03-03 |
Ciba-Geigy Corporation |
Staurosporine derivatives substituted at methylamino nitrogen
|
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
WO2003070887A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
KR20070114753A
(ko)
*
|
2005-02-18 |
2007-12-04 |
아브락시스 바이오사이언스 인크. |
치료제의 조합 및 투여 방식, 및 조합 요법
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
WO2007058627A1
(en)
|
2005-11-16 |
2007-05-24 |
S*Bio Pte Ltd |
Oxygen linked pyrimidine derivatives
|
|
MY162157A
(en)
|
2007-04-16 |
2017-05-31 |
Abbott Lab |
Substituted indole mcl-1 inhibitors
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
GB0806652D0
(en)
|
2008-04-11 |
2008-05-14 |
Glaxo Group Ltd |
Anhydrous crystal form of orvepitant maleate
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010120336A1
(en)
*
|
2009-04-15 |
2010-10-21 |
Poniard Pharmaceuticals, Inc. |
High bioavailability oral picoplatin anti-cancer therapy
|
|
JP4965623B2
(ja)
|
2009-09-30 |
2012-07-04 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
|
|
EA027622B1
(ru)
*
|
2010-02-05 |
2017-08-31 |
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" |
Твердофазные формы макроциклических ингибиторов киназы
|
|
US20110251216A1
(en)
|
2010-02-19 |
2011-10-13 |
The Regents Of The University Of Michigan |
Compositions and methods for inhibiting ezh2
|
|
EP2560637B1
(en)
|
2010-04-06 |
2018-11-07 |
Fred Hutchinson Cancer Research Center |
Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
BR112013005806B1
(pt)
|
2010-09-10 |
2022-05-10 |
Epizyme, Inc |
Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
|
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
CA2850570A1
(en)
|
2011-09-30 |
2013-04-04 |
Glaxosmithkline Llc |
Methods of treating cancer
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
RU2704445C2
(ru)
|
2012-03-12 |
2019-10-28 |
Эпизайм, Инк. |
Ингибиторы ezh2 человека и способы их применения
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2014022332A1
(en)
|
2012-07-31 |
2014-02-06 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
CA2887243C
(en)
|
2012-10-15 |
2024-04-09 |
Epizyme, Inc. |
Methods of treating cancer
|
|
MX386473B
(es)
|
2013-02-21 |
2025-03-18 |
Pfizer |
Formas solidas de un inhibidor de cdk4/6 selectivo
|
|
US10344088B2
(en)
|
2013-03-15 |
2019-07-09 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
WO2015036499A1
(en)
|
2013-09-11 |
2015-03-19 |
Medimmune Limited |
Anti-b7-h1 antibodies for treating tumors
|
|
AU2015225867B2
(en)
|
2014-03-07 |
2020-02-06 |
University Health Network |
Methods and compositions for modifying the immune response
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
NZ723859A
(en)
|
2014-03-14 |
2023-01-27 |
Servier Lab |
Pharmaceutical compositions of therapeutically active compounds and their uses
|
|
WO2017165732A1
(en)
|
2016-03-24 |
2017-09-28 |
Tragara Pharmaceuticals, Inc. |
Treatment of cancer with tg02
|
|
MX2020001875A
(es)
|
2017-08-18 |
2020-07-29 |
Tragara Pharmaceuticals Inc |
Forma polimorfica de tg02.
|